Myoelectric signal patterns can be used to predict the intended movements of amputees for prosthesis activation. Real-world prosthesis use introduces a variety of unpredictable conditional influences on these patterns, hindering the performance of classification algorithms and potentially leading to device abandonment. We have discovered a state-of-the-art classification method which is significantly more tolerant to these conditional influences. In our prior work, we presented a robust sparsity-based adaptive classification method that is tolerant to pattern deviations resulting from untrained limb positions and the prosthesis load. Herein, we demonstrate that this method is tolerant to the shifting or misalignment of the contact-electrode array which occurs during prosthesis use. We demonstrate the robustness of this approach in untrained electrode-site locations for amputee and able-bodied subjects, and report significant performance improvements over conventional myoelectric pattern recognition approaches. By showing that a single, unified method is robust across a variety of real-world condition spaces, clinicians are more likely to incorporate this method into myoelectric prosthesis controllers, resulting in improved utility and increased adoption among amputee users.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789096 | PMC |
http://dx.doi.org/10.1109/biocas.2017.8325201 | DOI Listing |
J Educ Health Promot
November 2024
Department of Neurologist, Neurologist Research Center, Faculty of Medical Sciences, Isfahan, Iran.
Background: Multiple sclerosis is a central neurogenic demyelinating disease. This is one of the most common neurological diseases in humans and is the most debilitating at a young age. Symptoms of multiple sclerosis include vision problems, balance problems, dizziness, sensory disturbances, chronic neuropathy, and fatigue.
View Article and Find Full Text PDFOsteoarthr Cartil Open
March 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.
Background: Chronic low back pain is a major cause of pain and disability with limited effective therapies. Metformin is a safe, inexpensive, well-tolerated drug that has pleotropic effects, including effects on pain pathways that may influence low back pain. The aim of this randomised, double-blind, placebo-controlled trial is to determine whether metformin reduces low back pain over 4 months in individuals with chronic low back pain.
View Article and Find Full Text PDFJ Allergy Clin Immunol Glob
February 2025
Division of Allergy, Immunology, Rheumatology, Rochester Regional Health.
Background: Penicillin allergy is reported in 5% to 15% of the world population, with 3% to 10% of pregnant women reporting the same. However, more than 90% of these patients can tolerate penicillin after appropriate evaluation. Penicillin is indicated for various issues that arise in pregnancy, and a history of allergy can have negative individual and public health consequences.
View Article and Find Full Text PDFERJ Open Res
January 2025
Kamada Ltd., Rehovot, Israel.
Background: Alpha-1 antitrypsin (AAT)-deficient individuals have a greater risk for developing COPD than individuals with normal AAT levels.
Methods: This was a double-blind, randomised, parallel group, placebo-controlled trial to examine the safety and tolerability of "Kamada-AAT for Inhalation" (inhaled AAT) in subjects with AAT deficiency, and to explore its effect on AAT and biomarkers in the lung epithelial lining fluid (ELF). 36 patients with severe AAT deficiency were randomised 2:1 to receive 80 mg or 160 mg inhaled AAT or placebo once daily for 12 weeks.
J Immunother Precis Oncol
February 2025
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Introduction: Advanced penile squamous cell carcinoma (pSCC) is a rare and aggressive malignancy with a poor prognosis and an unmet need for biomarkers. We performed a retrospective evaluation of real-world efficacy, safety outcomes, and baseline inflammatory biomarkers in patients with advanced pSCC treated with immune checkpoint inhibitors (ICIs).
Methods: We performed a retrospective review of patients with advanced pSCC who received ICIs from 2012 to 2023 at the Winship Cancer Institute of Emory University in Atlanta, GA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!